Icon to slash costs amid pandemic as 65% of its trial sites disrupted by COVID-19

As CROs report their first-quarter financials, Icon has issued some grim warnings about how much COVID-19 and the resultant lockdowns are hitting its business.

Icon to slash costs amid pandemic as 65% of its trial sites disrupted by COVID-19
As CROs report their first-quarter financials, Icon has issued some grim warnings about how much COVID-19 and the resultant lockdowns are hitting its business.